Get a Quote
Our Team

Prof. Steffen Hering

Chief Executive Officer & Founder

Prof. Steffen Hering

Biography Prof. Hering

Expert in pharmacology of ion channels with over 45 years of research experience. While serving as a professor of pharmacology and toxicology at the University of Vienna he founded ChanPharm in 2014. CEO of ChanPharm since 2019.

Education & Career

1983 — Dr. med. (doctor medicinae) and graduation as specialist in physiology. 1988 — Habilitation "doctor scientiae medicinae" at Academy of Science, Berlin. 1988–89 — Welcome Trust Fellow at St. George's Hospital, London. 1995 — Venia Legendi "Pharmacology and Toxicology" at University of Innsbruck. 2003 — Full Professor and Chairman of the Department of Pharmacology and Toxicology at the University of Vienna.

In 2011 he initiated the PhD program "Ion channels as molecular drug targets (MolTag)" and served for 10 years as its speaker. He is author of more than 300 scientific publications on ion channels and of 27 patent applications. In 2014 he founded ChanPharm; CEO of ChanPharm since 2019.

Selected Contributions to Ion Channel Research

He pioneered voltage clamp studies on isolated adult myocardial cells (Bodewei et al. 1982) and performed first studies on the mechanism of local anesthetics on their sodium channels (Hering et al. 1983). Later he focused at the University of Innsbruck on gating and pharmacology of voltage-gated calcium channels and their role in migraine (Hering et al. 2000).

His team discovered jointly with the group of Marion Moe (University of Otago, New Zealand) the role of a mutation in a calcium channel (Cav1.4) in a retinal disorder linked to incomplete congenital stationary night blindness (Hemara-Wahanui et al. 2005).

From 2008–2023 his team contributed in close collaboration with Matthias Hamburger (Biocenter Basel) to the discovery of 21 novel natural product GABA(A) receptor modulators and several natural product hERG channel inhibitors. More recently his research focused on the role of hERG channels in arrhythmogenesis (Saxena et al. 2017), proarrhythmic properties of natural products (Baburin et al. 2018), and the development of refined methods for cardiotoxicity studies on stem cell-derived cardiomyocytes (Baltov et al. 2023) making use of 2D and 3D culture systems (Schmidt et al. 2023).

Selected Publications

  1. 1.
    Bodewei R, Hering S, Lemke B, Rosenshtraukh LV, Undrovinas AI, Wollenberger A. Characterization of the fast sodium current in isolated rat myocardial cells: simulation of the clamped membrane potential.
    J Physiol. 1982 Apr;325:301-15. doi: 10.1113/jphysiol.1982.sp014151. PubMed PMC
  2. 2.
    Hering S, Bodewei R, Wollenberger A. Sodium current in freshly isolated and in cultured single rat myocardial cells: frequency and voltage-dependent block by mexiletine.
    J Mol Cell Cardiol. 1983 Jul;15(7):431-44. doi: 10.1016/0022-2828(83)90263-8. PubMed
  3. 3.
    Hering S, Bodewei R, Schubert B, Krause EG, Wollenberger A. Trapidil and other 5-triazolo-(1, 5-alpha)-pyrimidine derivatives as calcium channel blockers in 108CC5 cells.
    Biomed Biochim Acta. 1985;44(5):K37-41. PubMed
  4. 4.
    Bodewei R, Hering S, Schubert B, Winkler J, Wollenberger A. Calcium channel block by phenytoin in neuroblastoma x glioma hybrid cells.
    Biomed Biochim Acta. 1985;44(7-8):1229-37. PubMed
  5. 5.
    Bodewei R, Hering S, Schubert B, Wollenberger A. Sodium and calcium currents in neuroblastoma x glioma hybrid cells before and after morphological differentiation by dibutyryl cyclic AMP.
    Gen Physiol Biophys. 1985 Apr;4(2):113-27. PubMed
  6. 6.
    Hering S, Bodewei R, Schubert B, Rohde K, Wollenberger A. A kinetic analysis of the inward calcium current in 108CC15 neuroblastoma x glioma hybrid cells.
    Gen Physiol Biophys. 1985 Apr;4(2):129-41. PubMed
  7. 7.
    Schubert B, Hering S, Bodewei R, Rosenshtraukh LV, Wollenberger A. Use- and voltage-dependent depression by ethmozine (moricizine) of the rapid inward sodium current in single rat ventricular muscle cells.
    J Cardiovasc Pharmacol. 1986 Mar-Apr;8(2):358-66. doi: 10.1097/00005344-198603000-00019. PubMed
  8. 8.
    Schubert B, Bodewei R, Hering S, Wollenberger A. A patch clamp study of the action of ethacyzine on the rapid inward sodium current in single rat heart muscle cells.
    Eur J Pharmacol. 1986 Jul 31;126(3):309-12. doi: 10.1016/0014-2999(86)90063-4. PubMed
  9. 9.
    Knaus HG, Striessnig J, Hering S, Marrer S, Schwenner E, Höltje HD, Glossmann H. [35S]sadopine, a novel high affinity, high specific activity, L-type Ca2+ channel probe: characterization of two equipotent diastereomers with opposite allosteric properties.
    Mol Pharmacol. 1992 Feb;41(2):298-307. PubMed
  10. 10.
    Strübing C, Hering S, Glossmann H. Evidence for an external location of the dihydropyridine agonist receptor site on smooth muscle and skeletal muscle calcium channels.
    Br J Pharmacol. 1993 Apr;108(4):884-91. doi: 10.1111/j.1476-5381.1993.tb13482.x. PubMed PMC
  11. 11.
    Hering S, Savchenko A, Strübing C, Lakitsch M, Striessnig J. Extracellular localization of the benzothiazepine binding domain of L-type Ca2+ channels.
    Mol Pharmacol. 1993 May;43(5):820-6. PubMed
  12. 12.
    Glossmann H, Hering S, Savchenko A, Berger W, Friedrich K, Garcia ML, Goetz MA, Liesch JM, Zink DL, Kaczorowski GJ. A light stabilizer (Tinuvin 770) that elutes from polypropylene plastic tubes is a potent L-type Ca(2+)-channel blocker.
    Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9523-7. doi: 10.1073/pnas.90.20.9523. PubMed PMC
  13. 13.
    Grabner M, Wang Z, Mitterdorfer J, Rosenthal F, Charnet P, Savchenko A, Hering S, Ren D, Hall LM, Glossmann H. Cloning and functional expression of a neuronal calcium channel beta subunit from house fly (Musca domestica).
    J Biol Chem. 1994 Sep 23;269(38):23668-74. PubMed
  14. 14.
    Savchenko A, Glossmann H, Hering S. Improved micro-perfusion chamber for multiple and rapid solution exchange in adherent single cells.
    Pflugers Arch. 1995 Jan;429(3):436-42. doi: 10.1007/BF00374161. PubMed
  15. 15.
    Wang Z, Grabner M, Berjukow S, Savchenko A, Glossmann H, Hering S. Chimeric L-type Ca2+ channels expressed in Xenopus laevis oocytes reveal role of repeats III and IV in activation gating.
    J Physiol. 1995 Jul 1;486 ( Pt 1)(Pt 1):131-7. doi: 10.1113/jphysiol.1995.sp020797. PubMed PMC
  16. 16.
    Grabner M, Wang Z, Hering S, Striessnig J, Glossmann H. Transfer of 1,4-dihydropyridine sensitivity from L-type to class A (BI) calcium channels.
    Neuron. 1996 Jan;16(1):207-18. doi: 10.1016/s0896-6273(00)80037-9. PubMed
  17. 17.
    Döring F, Degtiar VE, Grabner M, Striessnig J, Hering S, Glossman H. Transfer of L-type calcium channel IVS6 segment increases phenylalkylamine sensitivity of alpha1A.
    J Biol Chem. 1996 May 17;271(20):11745-9. doi: 10.1074/jbc.271.20.11745. PubMed
  18. 18.
    Berjukow S, Döring F, Froschmayr M, Grabner M, Glossmann H, Hering S. Endogenous calcium channels in human embryonic kidney (HEK293) cells.
    Br J Pharmacol. 1996 Jun;118(3):748-54. doi: 10.1111/j.1476-5381.1996.tb15463.x. PubMed PMC
  19. 19.
    Hering S, Aczél S, Grabner M, Döring F, Berjukow S, Mitterdorfer J, Sinnegger MJ, Striessnig J, Degtiar VE, Wang Z, Glossmann H. Transfer of high sensitivity for benzothiazepines from L-type to class A (BI) calcium channels.
    J Biol Chem. 1996 Oct 4;271(40):24471-5. doi: 10.1074/jbc.271.40.24471. PubMed
  20. 20.
    Pichler M, Wang Z, Grabner-Weiss C, Reimer D, Hering S, Grabner M, Glossmann H, Striessnig J. Block of P/Q-type calcium channels by therapeutic concentrations of aminoglycoside antibiotics.
    Biochemistry. 1996 Nov 19;35(46):14659-64. doi: 10.1021/bi961657t. PubMed
  21. 21.
    Degtiar VE, Aczél S, Döring F, Timin EN, Berjukow S, Kimball D, Mitterdorfer J, Hering S. Calcium channel block by (-)devapamil is affected by the sequence environment and composition of the phenylalkylamine receptor site.
    Biophys J. 1997 Jul;73(1):157-67. doi: 10.1016/S0006-3495(97)78056-1. PubMed PMC
  22. 22.
    Sinnegger MJ, Wang Z, Grabner M, Hering S, Striessnig J, Glossmann H, Mitterdorfer J. Nine L-type amino acid residues confer full 1,4-dihydropyridine sensitivity to the neuronal calcium channel alpha1A subunit. Role of L-type Met1188.
    J Biol Chem. 1997 Oct 31;272(44):27686-93. doi: 10.1074/jbc.272.44.27686. PubMed
  23. 23.
    Hering S, Aczél S, Kraus RL, Berjukow S, Striessnig J, Timin EN. Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: role of inactivation.
    Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13323-8. doi: 10.1073/pnas.94.24.13323. PubMed PMC
  24. 24.
    Striessnig J, Grabner M, Mitterdorfer J, Hering S, Sinnegger MJ, Glossmann H. Structural basis of drug binding to L Ca2+ channels.
    Trends Pharmacol Sci. 1998 Mar;19(3):108-15. doi: 10.1016/s0165-6147(98)01171-7. PubMed
  25. 25.
    Kraus RL, Sinnegger MJ, Glossmann H, Hering S, Striessnig J. Familial hemiplegic migraine mutations change alpha1A Ca2+ channel kinetics.
    J Biol Chem. 1998 Mar 6;273(10):5586-90. doi: 10.1074/jbc.273.10.5586. PubMed
  26. 26.
    Hering S. Small-volume and rapid extracellular solution exchange around Xenopus oocytes during voltage-clamp recordings.
    Pflugers Arch. 1998 Jul;436(2):303-7. doi: 10.1007/s004240050636. PubMed
  27. 27.
    Mitterdorfer J, Grabner M, Kraus RL, Hering S, Prinz H, Glossmann H, Striessnig J. Molecular basis of drug interaction with L-type Ca2+ channels.
    J Bioenerg Biomembr. 1998 Aug;30(4):319-34. doi: 10.1023/a:1021933504909. PubMed
  28. 28.
    Aczél S, Kurka B, Hering S. Mechanism of voltage- and use-dependent block of class A Ca2+ channels by mibefradil.
    Br J Pharmacol. 1998 Oct;125(3):447-54. doi: 10.1038/sj.bjp.0702092. PubMed PMC
  29. 29.
    Kraus RL, Hering S, Grabner M, Ostler D, Striessnig J. Molecular mechanism of diltiazem interaction with L-type Ca2+ channels.
    J Biol Chem. 1998 Oct 16;273(42):27205-12. doi: 10.1074/jbc.273.42.27205. PubMed
  30. 30.
    Hering S, Berjukow S, Aczél S, Timin EN. Ca2+ channel block and inactivation: common molecular determinants.
    Trends Pharmacol Sci. 1998 Nov;19(11):439-43. doi: 10.1016/s0165-6147(98)01258-9. PubMed
  31. 31.
    Berjukow S, Gapp F, Aczél S, Sinnegger MJ, Mitterdorfer J, Glossmann H, Hering S. Sequence differences between alpha1C and alpha1S Ca2+ channel subunits reveal structural determinants of a guarded and modulated benzothiazepine receptor.
    J Biol Chem. 1999 Mar 5;274(10):6154-60. doi: 10.1074/jbc.274.10.6154. PubMed
  32. 32.
    Sokolov S, Weiss RG, Kurka B, Gapp F, Hering S. Inactivation determinant in the I-II loop of the Ca2+ channel alpha1-subunit and beta-subunit interaction affect sensitivity for the phenylalkylamine (-)gallopamil.
    J Physiol. 1999 Sep 1;519 Pt 2(Pt 2):315-22. doi: 10.1111/j.1469-7793.1999.0315m.x. PubMed PMC
  33. 33.
    Berjukow S, Marksteiner R, Gapp F, Sinnegger MJ, Hering S. Molecular mechanism of calcium channel block by isradipine. Role of a drug-induced inactivated channel conformation.
    J Biol Chem. 2000 Jul 21;275(29):22114-20. doi: 10.1074/jbc.M908836199. PubMed
  34. 34.
    Sokolov S, Weiss RG, Timin EN, Hering S. Modulation of slow inactivation in class A Ca2+ channels by beta-subunits.
    J Physiol. 2000 Sep 15;527 Pt 3(Pt 3):445-54. doi: 10.1111/j.1469-7793.2000.t01-1-00445.x. PubMed PMC
  35. 35.
    Hering S, Berjukow S, Sokolov S, Marksteiner R, Weiss RG, Kraus R, Timin EN. Molecular determinants of inactivation in voltage-gated Ca2+ channels.
    J Physiol. 2000 Oct 15;528 Pt 2(Pt 2):237-49. doi: 10.1111/j.1469-7793.2000.t01-1-00237.x. PubMed PMC
  36. 36.
    Berjukow S, Marksteiner R, Sokolov S, Weiss RG, Margreiter E, Hering S. Amino acids in segment IVS6 and beta-subunit interaction support distinct conformational changes during Ca(v)2.1 inactivation.
    J Biol Chem. 2001 May 18;276(20):17076-82. doi: 10.1074/jbc.M010491200. Epub 2001 Mar 7. PubMed
  37. 37.
    Berjukow S, Hering S. Voltage-dependent acceleration of Ca(v)1.2 channel current decay by (+)- and (-)-isradipine.
    Br J Pharmacol. 2001 Aug;133(7):959-66. doi: 10.1038/sj.bjp.0704181. PubMed PMC
  38. 38.
    Sokolov S, Timin E, Hering S. On the role of Ca(2+)- and voltage-dependent inactivation in Ca(v)1.2 sensitivity for the phenylalkylamine (-)gallopamil.
    Circ Res. 2001 Oct 12;89(8):700-8. doi: 10.1161/hh2001.098983. PubMed
  39. 39.
    Marksteiner R, Schurr P, Berjukow S, Margreiter E, Perez-Reyes E, Hering S. Inactivation determinants in segment IIIS6 of Ca(v)3.1.
    J Physiol. 2001 Nov 15;537(Pt 1):27-34. doi: 10.1111/j.1469-7793.2001.0027k.x. PubMed PMC
  40. 40.
    Hering S. beta-Subunits: fine tuning of Ca(2+) channel block.
    Trends Pharmacol Sci. 2002 Nov;23(11):509-13. doi: 10.1016/s0165-6147(02)02104-1. PubMed
  41. 41.
    Berjukow S, Margreiter E, Marksteiner R, Strasser H, Bartsch G, Hering S. Membrane properties of single muscle cells of the rhabdosphincter of the male urethra.
    Prostate. 2004 Feb 15;58(3):238-47. doi: 10.1002/pros.10334. PubMed
  42. 42.
    Kamelger FS, Marksteiner R, Margreiter E, Klima G, Wechselberger G, Hering S, Piza H. A comparative study of three different biomaterials in the engineering of skeletal muscle using a rat animal model.
    Biomaterials. 2004 Apr;25(9):1649-55. doi: 10.1016/s0142-9612(03)00520-9. PubMed
  43. 43.
    Ott HC, Bonaros N, Marksteiner R, Wolf D, Margreiter E, Schachner T, Laufer G, Hering S. Combined transplantation of skeletal myoblasts and bone marrow stem cells for myocardial repair in rats.
    Eur J Cardiothorac Surg. 2004 Apr;25(4):627-34. doi: 10.1016/j.ejcts.2003.12.031. PubMed
  44. 44.
    Sinnegger-Brauns MJ, Hetzenauer A, Huber IG, Renström E, Wietzorrek G, Berjukov S, Cavalli M, Walter D, Koschak A, Waldschütz R, Hering S, Bova S, Rorsman P, Pongs O, Singewald N, Striessnig J. Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels.
    J Clin Invest. 2004 May;113(10):1430-9. doi: 10.1172/JCI20208. PubMed PMC
  45. 45.
    Ott HC, Berjukow S, Marksteiner R, Margreiter E, Böck G, Laufer G, Hering S. On the fate of skeletal myoblasts in a cardiac environment: down-regulation of voltage-gated ion channels.
    J Physiol. 2004 Aug 1;558(Pt 3):793-805. doi: 10.1113/jphysiol.2003.060186. Epub 2004 Jun 11. PubMed PMC
  46. 46.
    Strasser H, Berjukow S, Marksteiner R, Margreiter E, Hering S, Bartsch G, Hering S. Stem cell therapy for urinary stress incontinence.
    Exp Gerontol. 2004 Sep;39(9):1259-65. doi: 10.1016/j.exger.2004.07.003. PubMed
  47. 47.
    Hohaus A, Beyl S, Kudrnac M, Berjukow S, Timin EN, Marksteiner R, Maw MA, Hering S. Structural determinants of L-type channel activation in segment IIS6 revealed by a retinal disorder.
    J Biol Chem. 2005 Nov 18;280(46):38471-7. doi: 10.1074/jbc.M507013200. Epub 2005 Sep 12. PubMed PMC
  48. 48.
    Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S. Pharmacological properties of GABAA receptors containing gamma1 subunits.
    Mol Pharmacol. 2006 Feb;69(2):640-9. doi: 10.1124/mol.105.017236. Epub 2005 Nov 4. PubMed
  49. 49.
    Peterbauer T, Heitz J, Olbrich M, Hering S. Simple and versatile methods for the fabrication of arrays of live mammalian cells.
    Lab Chip. 2006 Jul;6(7):857-63. doi: 10.1039/b601803c. Epub 2006 May 8. PubMed
  50. 50.
    Baburin I, Beyl S, Hering S. Automated fast perfusion of Xenopus oocytes for drug screening.
    Pflugers Arch. 2006 Oct;453(1):117-23. doi: 10.1007/s00424-006-0125-y. Epub 2006 Sep 5. PubMed PMC
  51. 51.
    Beyl S, Timin EN, Hohaus A, Stary A, Kudrnac M, Guy RH, Hering S. Probing the architecture of an L-type calcium channel with a charged phenylalkylamine: evidence for a widely open pore and drug trapping.
    J Biol Chem. 2007 Feb 9;282(6):3864-70. doi: 10.1074/jbc.M609153200. Epub 2006 Nov 30. PubMed PMC
  52. 52.
    Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering S. Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity.
    Neuropharmacology. 2007 Jul;53(1):178-87. doi: 10.1016/j.neuropharm.2007.04.018. Epub 2007 May 13. PubMed
  53. 53.
    Stork D, Timin EN, Berjukow S, Huber C, Hohaus A, Auer M, Hering S. State dependent dissociation of HERG channel inhibitors.
    Br J Pharmacol. 2007 Aug;151(8):1368-76. doi: 10.1038/sj.bjp.0707356. Epub 2007 Jun 25. PubMed PMC
  54. 54.
    Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp B. Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid.
    Planta Med. 2008 Jan;74(1):19-24. doi: 10.1055/s-2007-993761. Epub 2007 Dec 19. PubMed
  55. 55.
    Hering S, Beyl S, Stary A, Kudrnac M, Hohaus A, Guy HR, Timin E. Pore stability and gating in voltage-activated calcium channels.
    Channels (Austin). 2008 Mar-Apr;2(2):61-9. doi: 10.4161/chan.2.2.5999. Epub 2008 Mar 14. PubMed PMC
  56. 56.
    Stary A, Kudrnac M, Beyl S, Hohaus A, Timin EN, Wolschann P, Guy HR, Hering S. Molecular dynamics and mutational analysis of a channelopathy mutation in the IIS6 helix of Ca V 1.2.
    Channels (Austin). 2008 May-Jun;2(3):216-23. doi: 10.4161/chan.2.3.6160. Epub 2008 May 18. PubMed PMC
  57. 57.
    Stary A, Shafrir Y, Hering S, Wolschann P, Guy HR. Structural model of the Ca V 1.2 pore.
    Channels (Austin). 2008 May-Jun;2(3):210-5. doi: 10.4161/chan.2.3.6158. Epub 2008 May 18. PubMed
  58. 58.
    Baburin I, Khom S, Timin E, Hohaus A, Sieghart W, Hering S. Estimating the efficiency of benzodiazepines on GABA(A) receptors comprising gamma1 or gamma2 subunits.
    Br J Pharmacol. 2008 Oct;155(3):424-33. doi: 10.1038/bjp.2008.271. Epub 2008 Jul 7. PubMed PMC
  59. 59.
    Kudrnac M, Beyl S, Hohaus A, Stary A, Peterbauer T, Timin E, Hering S. Coupled and independent contributions of residues in IS6 and IIS6 to activation gating of CaV1.2.
    J Biol Chem. 2009 May 1;284(18):12276-84. doi: 10.1074/jbc.M808402200. Epub 2009 Mar 5. PubMed PMC
  60. 60.
    Beyl S, Kügler P, Kudrnac M, Hohaus A, Hering S, Timin E. Different pathways for activation and deactivation in CaV1.2: a minimal gating model.
    J Gen Physiol. 2009 Sep;134(3):231-41; S1-2. doi: 10.1085/jgp.200910272. Epub 2009 Aug 17. PubMed PMC
  61. 61.
    Thai KM, Windisch A, Stork D, Weinzinger A, Schiesaro A, Guy RH, Timin EN, Hering S, Ecker GF. The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives.
    ChemMedChem. 2010 Mar 1;5(3):436-42. doi: 10.1002/cmdc.200900374. PubMed
  62. 62.
    Khom S, Strommer B, Ramharter J, Schwarz T, Schwarzer C, Erker T, Ecker GF, Mulzer J, Hering S. Valerenic acid derivatives as novel subunit-selective GABAA receptor ligands - in vitro and in vivo characterization.
    Br J Pharmacol. 2010 Sep;161(1):65-78. doi: 10.1111/j.1476-5381.2010.00865.x. PubMed PMC
  63. 63.
    Cicek SS, Khom S, Taferner B, Hering S, Stuppner H. Bioactivity-guided isolation of GABA(A) receptor modulating constituents from the rhizomes of Actaea racemosa.
    J Nat Prod. 2010 Dec 27;73(12):2024-8. doi: 10.1021/np100479w. Epub 2010 Nov 17. PubMed
  64. 64.
    Beyl S, Depil K, Hohaus A, Stary-Weinzinger A, Timin E, Shabbir W, Kudrnac M, Hering S. Physicochemical properties of pore residues predict activation gating of Ca V1.2: a correlation mutation analysis.
    Pflugers Arch. 2011 Jan;461(1):53-63. doi: 10.1007/s00424-010-0885-2. Epub 2010 Oct 7. PubMed PMC
  65. 65.
    Shabbir W, Beyl S, Timin EN, Schellmann D, Erker T, Hohaus A, Hockerman GH, Hering S. Interaction of diltiazem with an intracellularly accessible binding site on Ca(V)1.2.
    Br J Pharmacol. 2011 Mar;162(5):1074-82. doi: 10.1111/j.1476-5381.2010.01091.x. PubMed PMC
  66. 66.
    Windisch A, Timin E, Schwarz T, Stork-Riedler D, Erker T, Ecker G, Hering S. Trapping and dissociation of propafenone derivatives in HERG channels.
    Br J Pharmacol. 2011 Apr;162(7):1542-52. doi: 10.1111/j.1476-5381.2010.01159.x. PubMed PMC
  67. 67.
    Taferner B, Schuehly W, Huefner A, Baburin I, Wiesner K, Ecker GF, Hering S. Modulation of GABAA-receptors by honokiol and derivatives: subtype selectivity and structure-activity relationship.
    J Med Chem. 2011 Aug 11;54(15):5349-61. doi: 10.1021/jm200186n. Epub 2011 Jul 12. PubMed
  68. 68.
    Depil K, Beyl S, Stary-Weinzinger A, Hohaus A, Timin E, Hering S. Timothy mutation disrupts the link between activation and inactivation in Ca(V)1.2 protein.
    J Biol Chem. 2011 Sep 9;286(36):31557-64. doi: 10.1074/jbc.M111.255273. Epub 2011 Jun 17. PubMed PMC
  69. 69.
    Singhuber J, Baburin I, Ecker GF, Kopp B, Hering S. Insights into structure-activity relationship of GABAA receptor modulating coumarins and furanocoumarins.
    Eur J Pharmacol. 2011 Oct 1;668(1-2):57-64. doi: 10.1016/j.ejphar.2011.06.034. Epub 2011 Jul 5. PubMed PMC
  70. 70.
    Beyl S, Depil K, Hohaus A, Stary-Weinzinger A, Linder T, Timin E, Hering S. Neutralisation of a single voltage sensor affects gating determinants in all four pore-forming S6 segments of Ca(V)1.2: a cooperative gating model.
    Pflugers Arch. 2012 Oct;464(4):391-401. doi: 10.1007/s00424-012-1144-5. Epub 2012 Sep 2. PubMed PMC
  71. 71.
    Khom S, Strommer B, Schöffmann A, Hintersteiner J, Baburin I, Erker T, Schwarz T, Schwarzer C, Zaugg J, Hamburger M, Hering S. GABAA receptor modulation by piperine and a non-TRPV1 activating derivative.
    Biochem Pharmacol. 2013 Jun 15;85(12):1827-36. doi: 10.1016/j.bcp.2013.04.017. Epub 2013 Apr 25. PubMed PMC
  72. 72.
    Beyl S, Kügler P, Hohaus A, Depil K, Hering S, Timin E. Methods for quantification of pore-voltage sensor interaction in Ca(V)1.2.
    Pflugers Arch. 2014 Feb;466(2):265-74. doi: 10.1007/s00424-013-1319-8. Epub 2013 Jul 20. PubMed PMC
  73. 73.
    Rueda DC, Schöffmann A, De Mieri M, Raith M, Jähne EA, Hering S, Hamburger M. Identification of dihydrostilbenes in Pholidota chinensis as a new scaffold for GABAA receptor modulators.
    Bioorg Med Chem. 2014 Feb 15;22(4):1276-84. doi: 10.1016/j.bmc.2014.01.008. Epub 2014 Jan 10. PubMed
  74. 74.
    Schramm A, Saxena P, Chlebek J, Cahlíková L, Baburin I, Hering S, Hamburger M. Natural products as potential human ether-a-go-go-related gene channel inhibitors - screening of plant-derived alkaloids.
    Planta Med. 2014 Jun;80(8-9):740-6. doi: 10.1055/s-0034-1368590. Epub 2014 Jun 25. PubMed
  75. 75.
    Schöffmann A, Wimmer L, Goldmann D, Khom S, Hintersteiner J, Baburin I, Schwarz T, Hintersteininger M, Pakfeifer P, Oufir M, Hamburger M, Erker T, Ecker GF, Mihovilovic MD, Hering S. Efficient modulation of γ-aminobutyric acid type A receptors by piperine derivatives.
    J Med Chem. 2014 Jul 10;57(13):5602-19. doi: 10.1021/jm5002277. Epub 2014 Jun 27. PubMed PMC
  76. 76.
    Hintersteiner J, Haider M, Luger D, Schwarzer C, Reznicek G, Jäger W, Khom S, Mihovilovic MD, Hering S. Esters of valerenic acid as potential prodrugs.
    Eur J Pharmacol. 2014 Jul 15;735(100):123-31. doi: 10.1016/j.ejphar.2014.03.019. Epub 2014 Mar 27. PubMed PMC
  77. 77.
    Schramm A, Jähne EA, Baburin I, Hering S, Hamburger M. Natural products as potential human ether-a-go-go-related gene channel inhibitors - outcomes from a screening of widely used herbal medicines and edible plants.
    Planta Med. 2014 Aug;80(12):1045-50. doi: 10.1055/s-0034-1382907. Epub 2014 Aug 4. PubMed
  78. 78.
    Strommer B, Khom S, Kastenberger I, Cicek SS, Stuppner H, Schwarzer C, Hering S. A cycloartane glycoside derived from Actaea racemosa L. modulates GABAA receptors and induces pronounced sedation in mice.
    J Pharmacol Exp Ther. 2014 Nov;351(2):234-42. doi: 10.1124/jpet.114.218024. Epub 2014 Aug 26. PubMed
  79. 79.
    Linder T, Saxena P, Timin E, Hering S, Stary-Weinzinger A. Structural insights into trapping and dissociation of small molecules in K+ channels.
    J Chem Inf Model. 2014 Nov 24;54(11):3218-28. doi: 10.1021/ci500353r. Epub 2014 Oct 21. PubMed
  80. 80.
    Rueda DC, Raith M, De Mieri M, Schöffmann A, Hering S, Hamburger M. Identification of dehydroabietc acid from Boswellia thurifera resin as a positive GABAA receptor modulator.
    Fitoterapia. 2014 Dec;99:28-34. doi: 10.1016/j.fitote.2014.09.002. Epub 2014 Sep 6. PubMed
  81. 81.
    Wimmer L, Schönbauer D, Pakfeifer P, Schöffmann A, Khom S, Hering S, Mihovilovic MD. Developing piperine towards TRPV1 and GABAA receptor ligands--synthesis of piperine analogs via Heck-coupling of conjugated dienes.
    Org Biomol Chem. 2015 Jan 28;13(4):990-4. doi: 10.1039/c4ob02242d. Epub 2014 Dec 1. PubMed
  82. 82.
    Du K, De Mieri M, Saxena P, Phungula KV, Wilhelm A, Hrubaru MM, van Rensburg E, Zietsman PC, Hering S, van der Westhuizen JH, Hamburger M. HPLC-Based Activity Profiling for hERG Channel Inhibitors in the South African Medicinal Plant Galenia africana.
    Planta Med. 2015 Aug;81(12-13):1154-62. doi: 10.1055/s-0035-1545929. Epub 2015 Apr 29. PubMed
  83. 83.
    Bernaskova M, Schoeffmann A, Schuehly W, Hufner A, Baburin I, Hering S. Nitrogenated honokiol derivatives allosterically modulate GABAA receptors and act as strong partial agonists.
    Bioorg Med Chem. 2015 Oct 15;23(20):6757-62. doi: 10.1016/j.bmc.2015.08.034. Epub 2015 Aug 28. PubMed
  84. 84.
    Luger D, Poli G, Wieder M, Stadler M, Ke S, Ernst M, Hohaus A, Linder T, Seidel T, Langer T, Khom S, Hering S. Identification of the putative binding pocket of valerenic acid on GABAA receptors using docking studies and site-directed mutagenesis.
    Br J Pharmacol. 2015 Nov;172(22):5403-13. doi: 10.1111/bph.13329. Epub 2015 Oct 25. PubMed PMC
  85. 85.
    Linder T, Bernsteiner H, Saxena P, Bauer F, Erker T, Timin E, Hering S, Stary-Weinzinger A. Drug trapping in hERG K+ channels: (not) a matter of drug size?
    Medchemcomm. 2016 Mar 1;7(3):512-518. doi: 10.1039/c5md00443h. Epub 2015 Dec 22. PubMed PMC
  86. 86.
    Saxena P, Zangerl-Plessl EM, Linder T, Windisch A, Hohaus A, Timin E, Hering S, Stary-Weinzinger A. New potential binding determinant for hERG channel inhibitors.
    Sci Rep. 2016 Apr 12;6:24182. doi: 10.1038/srep24182. PubMed PMC
  87. 87.
    Khom S, Hintersteiner J, Luger D, Haider M, Pototschnig G, Mihovilovic MD, Schwarzer C, Hering S. Analysis of β-Subunit-dependent GABAA Receptor Modulation and Behavioral Effects of Valerenic Acid Derivatives.
    J Pharmacol Exp Ther. 2016 Jun;357(3):580-90. doi: 10.1124/jpet.116.232983. Epub 2016 Apr 18. PubMed PMC
  88. 88.
    Beyl S, Hohaus A, Andranovits S, Timin E, Hering S. Upward movement of IS4 and IIIS4 is a rate-limiting stage in Cav1.2 activation.
    Pflugers Arch. 2016 Nov;468(11-12):1895-1907. doi: 10.1007/s00424-016-1895-5. Epub 2016 Oct 29. PubMed PMC
  89. 89.
    Li J, Casteels T, Frogne T, Ingvorsen C, Honoré C, Courtney M, Huber KVM, Schmitner N, Kimmel RA, Romanov RA, Sturtzel C, Lardeau CH, Klughammer J, Farlik M, Sdelci S, Vieira A, Avolio F, Briand F, Baburin I, Májek P, Pauler FM, Penz T, Stukalov A, Gridling M, Parapatics K, Barbieux C, Berishvili E, Spittler A, Colinge J, Bennett KL, Hering S, Sulpice T, Bock C, Distel M, Harkany T, Meyer D, Superti-Furga G, Collombat P, Hecksher-Sørensen J, Kubicek S. Artemisinins Target GABAA Receptor Signaling and Impair α Cell Identity.
    Cell. 2017 Jan 12;168(1-2):86-100.e15. doi: 10.1016/j.cell.2016.11.010. Epub 2016 Dec 1. PubMed PMC
  90. 90.
    Saxena P, Hortigon-Vinagre MP, Beyl S, Baburin I, Andranovits S, Iqbal SM, Costa A, IJzerman AP, Kügler P, Timin E, Smith GL, Hering S. Correlation between human ether-a-go-go-related gene channel inhibition and action potential prolongation.
    Br J Pharmacol. 2017 Sep;174(18):3081-3093. doi: 10.1111/bph.13942. Epub 2017 Aug 11. PubMed PMC
  91. 91.
    Andranovits S, Beyl S, Hohaus A, Zangerl-Plessl EM, Timin E, Hering S. Key role of segment IS4 in Cav1.2 inactivation: link between activation and inactivation.
    Pflugers Arch. 2017 Nov;469(11):1485-1493. doi: 10.1007/s00424-017-2038-3. Epub 2017 Aug 1. PubMed PMC
  92. 92.
    Baburin I, Varkevisser R, Schramm A, Saxena P, Beyl S, Szkokan P, Linder T, Stary-Weinzinger A, van der Heyden MAG, Houtman M, Takanari H, Jonsson M, Beekman JHD, Hamburger M, Vos MA, Hering S. Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are IKr blockers with proarrhythmic effects in vitro and in vivo.
    Pharmacol Res. 2018 May;131:150-163. doi: 10.1016/j.phrs.2018.02.024. Epub 2018 Mar 15. PubMed
  93. 93.
    Hering S, Zangerl-Plessl EM, Beyl S, Hohaus A, Andranovits S, Timin EN. Calcium channel gating.
    Pflugers Arch. 2018 Sep;470(9):1291-1309. doi: 10.1007/s00424-018-2163-7. Epub 2018 Jun 27. PubMed PMC
  94. 94.
    Stadler M, Monticelli S, Seidel T, Luger D, Salzer I, Boehm S, Holzer W, Schwarzer C, Urban E, Khom S, Langer T, Pace V, Hering S. Design, Synthesis, and Pharmacological Evaluation of Novel β2/3 Subunit-Selective γ-Aminobutyric Acid Type A (GABAA) Receptor Modulators.
    J Med Chem. 2019 Jan 10;62(1):317-341. doi: 10.1021/acs.jmedchem.8b00859. Epub 2018 Oct 23. PubMed
  95. 95.
    Qile M, Beekman HDM, Sprenkeler DJ, Houtman MJC, van Ham WB, Stary-Weinzinger A, Beyl S, Hering S, van den Berg DJ, de Lange ECM, Heitman LH, IJzerman AP, Vos MA, van der Heyden MAG. LUF7244, an allosteric modulator/activator of Kv 11.1 channels, counteracts dofetilide-induced torsades de pointes arrhythmia in the chronic atrioventricular block dog model.
    Br J Pharmacol. 2019 Oct;176(19):3871-3885. doi: 10.1111/bph.14798. Epub 2019 Aug 30. PubMed PMC
  96. 96.
    Thurner M, Deutsch M, Janke K, Messner F, Kreutzer C, Beyl S, Couillard-Després S, Hering S, Troppmair J, Marksteiner R. Generation of myogenic progenitor cell-derived smooth muscle cells for sphincter regeneration.
    Stem Cell Res Ther. 2020 Jun 12;11(1):233. doi: 10.1186/s13287-020-01749-w. PubMed PMC
  97. 97.
    Syafni N, Faleschini MT, Garifulina A, Danton O, Gupta MP, Hering S, Hamburger M. Clerodane Diterpenes from Casearia corymbosa as Allosteric GABAA Receptor Modulators.
    J Nat Prod. 2022 May 27;85(5):1201-1210. doi: 10.1021/acs.jnatprod.1c00840. Epub 2022 Apr 27. PubMed PMC
  98. 98.
    Garifulina A, Friesacher T, Stadler M, Zangerl-Plessl EM, Ernst M, Stary-Weinzinger A, Willam A, Hering S. β subunits of GABAA receptors form proton-gated chloride channels: Insights into the molecular basis.
    Commun Biol. 2022 Aug 3;5(1):784. doi: 10.1038/s42003-022-03720-2. PubMed PMC
  99. 99.
    Heider J, Kilian J, Garifulina A, Hering S, Langer T, Seidel T. Apo2ph4: A Versatile Workflow for the Generation of Receptor-based Pharmacophore Models for Virtual Screening.
    J Chem Inf Model. 2023 Jan 9;63(1):101-110. doi: 10.1021/acs.jcim.2c00814. Epub 2022 Dec 16. PubMed PMC
  100. 100.
    Baltov B, Beyl S, Baburin I, Reinhardt J, Szkokan P, Garifulina A, Timin E, Kraushaar U, Potterat O, Hamburger M, Kügler P, Hering S. Assay for evaluation of proarrhythmic effects of herbal products: Case study with 12 Evodia preparations.
    Toxicol Rep. 2023 Apr 26;10:589-599. doi: 10.1016/j.toxrep.2023.04.014. PubMed PMC
  101. 101.
    Faleschini T, Syafni N, Schulte HL, Garifulina A, Hering S, Espindola LS, Hamburger M. A neolignan from Connarus tuberosus as an allosteric GABAA receptor modulator at the neurosteroid binding site.
    Biomed Pharmacother. 2023 May;161:114498. doi: 10.1016/j.biopha.2023.114498. Epub 2023 Mar 10. PubMed
  102. 102.
    Schmidt C, Deyett A, Ilmer T, Haendeler S, Torres Caballero A, Novatchkova M, Netzer MA, Ceci Ginistrelli L, Mancheno Juncosa E, Bhattacharya T, Mujadzic A, Pimpale L, Jahnel SM, Cirigliano M, Reumann D, Tavernini K, Papai N, Hering S, Hofbauer P, Mendjan S. Multi-chamber cardioids unravel human heart development and cardiac defects.
    Cell. 2023 Dec 7;186(25):5587-5605.e27. doi: 10.1016/j.cell.2023.10.030. Epub 2023 Nov 28. PubMed

Send a request
Get a Quote

office@chanpharm.com
+43 1 997 80 51 | +43 660 223 2203